Literature DB >> 27779196

Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers.

Annarosa Floreani1, Chiara Mangini1, Anna Reig2, Irene Franceschet1, Nora Cazzagon1, Lisa Perini1, Llorenç Caballería2, Silvia Cocchio3, Vincenzo Baldo3, Albert Parés2.   

Abstract

OBJECTIVES: Primary biliary cholangitis (PBC) is often associated with other autoimmune diseases, but little is known about the influence of thyroid disease (TD) on the natural history of PBC. Our aim is to analyze the association between PBC and TD, and the latter's impact on the natural history of PBC at two European centers.
METHODS: The study involved 921 PBC patients enrolled between 1975 and 2015 in Padova (376 patients) and Barcelona (545 patients), with a mean follow-up of 126.9±91.7 months. Data were recorded on patients' histological stage at diagnosis, biochemical data, associated extrahepatic autoimmune conditions, and clinical events, including hepatic decompensation.
RESULTS: A total of 150 patients (16.3%) had TD, including 94 patients (10.2%) with Hashimoto's thyroiditis; 15 (1.6%) with Graves' disease; 22 (2.4%) with multinodular goiter; 7 (0.8%) with thyroid cancer; and 12 (1.3%) with other thyroid conditions. The prevalence of different types of TD was similar in Padova and Barcelona, except for Graves' disease and thyroid cancer, which were more frequent in the Padova cohort (15.7 vs. 5.0%, and 8.6 vs. 1.3%, respectively, P<0.05). Overall, there were no differences between PBC patients with and without TD in terms of their histological stage at diagnosis, hepatic decompensation events, occurrence of HCC, or liver transplantation rate. The presence of associated TD was not associated with lower survival for PBC patients in either cohort.
CONCLUSIONS: TDs, and autoimmune TD like Hashimoto's thyroiditis in particular, are often associated with PBC, but the presence of TD does not influence the rate of hepatic complications or the natural history of PBC.

Entities:  

Mesh:

Year:  2016        PMID: 27779196     DOI: 10.1038/ajg.2016.479

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  32 in total

1.  [Estimate of the prevalence of hypothyroidism in Spain based on the use of thyroid hormones (1996-1999)].

Authors:  C Morant Ginestar; J J Criado-Alvarez; R García-Pina; B Pérez Garrido
Journal:  Rev Esp Salud Publica       Date:  2001 Jul-Aug

2.  Elevation of serum immunoglobulin G in Hashimoto's thyroiditis and decrease after treatment with L-thyroxine in hypothyroid patients.

Authors:  Keishi Yamauchi; Takashi Yamada; Akira Sato; Kenzi Inazawa; Toru Aizawa
Journal:  Intern Med       Date:  2010-02-15       Impact factor: 1.271

Review 3.  Approach to the patient with nontoxic multinodular goiter.

Authors:  Rebecca S Bahn; M Regina Castro
Journal:  J Clin Endocrinol Metab       Date:  2011-05       Impact factor: 5.958

4.  Concurrent autoimmune diseases in patients with autoimmune hepatitis.

Authors:  Andreas Teufel; Arndt Weinmann; George J Kahaly; Catherine Centner; Anja Piendl; Marcus Wörns; Ansgar W Lohse; Peter R Galle; Stephan Kanzler
Journal:  J Clin Gastroenterol       Date:  2010-03       Impact factor: 3.062

Review 5.  Extrahepatic autoimmune conditions associated with primary biliary cirrhosis.

Authors:  Annarosa Floreani; Irene Franceschet; Nora Cazzagon; Alice Spinazzè; Alessandra Buja; Patrizia Furlan; Vincenzo Baldo; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 6.  Diagnosis and classification of Graves' disease.

Authors:  Francesca Menconi; Claudio Marcocci; Michele Marinò
Journal:  Autoimmun Rev       Date:  2014-01-12       Impact factor: 9.754

Review 7.  Primary biliary cirrhosis.

Authors:  Elizabeth J Carey; Ahmad H Ali; Keith D Lindor
Journal:  Lancet       Date:  2015-09-11       Impact factor: 79.321

8.  Extrahepatic malignancies in primary biliary cirrhosis: a comparative study at two European centers.

Authors:  Annarosa Floreani; Alice Spinazzè; Llorenc Caballeria; Ana Reig; Nora Cazzagon; Irene Franceschet; Alessandra Buja; Patrizia Furlan; Kenichi Harada; Patrick Sc Leung; M Eric Gershwin; Albert Pares
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

9.  Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

Authors:  Christophe Corpechot; Ludovico Abenavoli; Nabila Rabahi; Yves Chrétien; Tony Andréani; Catherine Johanet; Olivier Chazouillères; Raoul Poupon
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

Review 10.  Coronary Microvascular Function and Beyond: The Crosstalk between Hormones, Cytokines, and Neurotransmitters.

Authors:  Carlo Dal Lin; Francesco Tona; Elena Osto
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

View more
  5 in total

Review 1.  Antimitochondrial Antibodies: from Bench to Bedside.

Authors:  Francesca Colapietro; Ana Lleo; Elena Generali
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-29       Impact factor: 10.817

2.  The extrahepatic events of Asian patients with primary biliary cholangitis: A 30-year cohort study.

Authors:  Cheng-Yu Lin; Ya-Ting Cheng; Ming-Ling Chang; Rong-Nan Chien
Journal:  Sci Rep       Date:  2019-05-20       Impact factor: 4.379

3.  Thyroid Disease-Induced Hepatic Dysfunction: A Clinical Puzzle.

Authors:  Chimaobi M Anugwom; Thomas M Leventhal
Journal:  ACG Case Rep J       Date:  2021-04-14

Review 4.  Novel therapeutic targets for cholestatic and fatty liver disease.

Authors:  Michael Trauner; Claudia Daniela Fuchs
Journal:  Gut       Date:  2021-10-06       Impact factor: 23.059

Review 5.  Mesenchymal Stem Cells as New Therapeutic Agents for the Treatment of Primary Biliary Cholangitis.

Authors:  Aleksandar Arsenijevic; C Randall Harrell; Crissy Fellabaum; Vladislav Volarevic
Journal:  Anal Cell Pathol (Amst)       Date:  2017-12-19       Impact factor: 2.916

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.